Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ:TSVT)

4.950 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 Next >
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
From 2seventy bio, Inc.
Via Business Wire
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
From 2seventy bio, Inc.
Via Business Wire
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
From 2seventy bio
Via Business Wire
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference
From 2seventy bio
Via Business Wire
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
From 2seventy bio
Via Business Wire
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
From 2seventy bio
Via Business Wire
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
From 2seventy bio
Via Business Wire
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
From 2seventy bio, Inc.
Via Business Wire
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Proposed Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Provides Company Outlook for 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
From 2seventy bio, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.